Quest Diagnostics (DGX) continues to carve out a strong position in the biotech market. The stock has reached new milestones after forming a partnership with
Octave Bioscience for multiple sclerosis testing, and improving the laboratory testing experience through industry-first
Epic collaboration. Bellevue Group's new
$8.72 million investment in DGX further supports growth. DGX reported strong Q3 earnings and raised outlook, impressively increasing their valuation. Quarterly cash dividends were declared, and position in the company was boosted by
State Street Corp. The company's steady share price performance, strong revenue growth, collaborations, and acquisitions have also boosted its value and outlook. Projected
15.4% earnings growth refutes slower-growth narrative. Additionally, a newly formed partnership with Octave Bioscience for a
multiple sclerosis biomarker has enhanced innovation. Moreover, the recent
launch of nationwide pharmacogenomic test for precision medicine, collaboration with Google Cloud, and a joint venture with Corewell Health are promising indicators of DGX’s innovative thrust.
Quest Diagnostics DGX News Analytics from Thu, 30 Jan 2025 08:00:00 GMT to Sat, 13 Dec 2025 16:27:33 GMT -
Rating 7
- Innovation 6
- Information 8
- Rumor 4
